Anti-obesity drugs acting on the gastro-intestinal tract

Prescribe only as part of an overall plan for managing obesity in adults who have:

• BMI of 28.0 kg/m2 or more with associated risk factors, or
• BMI of 30.0 kg/m2 or more.
• Continue treatment for longer than 3 months only if the person has lost at least 5% of their initial body weight since starting drug treatment
• Continue for longer than 12 months only after discussing potential benefits and limitations with the patient.